Unusual Presentation of a Post-procedural Breast Hematoma: A Case Report

xlomafota13 shared this article with you from Inoreader Unusual Presentation of a Post-procedural Breast Hematoma: A Case Report Via In vivo (Athens, Greece) In Vivo. 2021 Sep-Oct;35(5):2957-2961. doi: 10.21873/invivo.12589. ABSTRACT BACKGROUND/AIM: Hematoma is the most frequent complication after Vacuum-Assisted Breast Biopsy (VABB) in 13% of cases. A direct communication channel with patients eases the diagnosis of VABB complications and ensures treatment at an early stage, as outpatients, in most cases. In 2020, due to the COVID-19 pandemic, we observed a reduction of self-reported postoperative complication leading to delay in the identification of harmful complications, therefore leading to need for more invasive treatment. CASE REPORT: A 50-year-old patient was admitted to the Emergency Department for dry cough, fever, chest discomfort, dyspnea, and slight confusion four days after VABB. Due to the reported symptoms, the patient was sent to our COVID-19 Emergency Department. The COVID-19 swab was negative. Ultrasound revealed a large hematoma at the biopsy site, with active blee ding. Open evacuation with accurate hemostasis was planned with rapid and complete resolution of the clinical symptoms. After surgery, the patient reported that she intentionally avoided admittance in the hospital due to the risk of COVID-19 infection. The patient was discharged in the first postoperative day and maintained in quarantine for 14 days. CONCLUSION: In the COVID-19 era due to the risk of hospital cross-infections, reduction of patient-doctor communication could lead to misdiagnosis, delay in recognition of procedural complications thus leading to requirement for invasive treatment, hospitalization, while also further multiplying the risk of COVID-19 infection. PMID:34410994 | DOI:10.21873/invivo.12589 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Patients With Active Cancer

xlomafota13 shared this article with you from Inoreader Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Patients With Active Cancer Via In vivo (Athens, Greece) In Vivo. 2021 Sep-Oct;35(5):2747-2753. doi: 10.21873/invivo.12559. ABSTRACT BACKGROUND/AIM: Although direct oral anti - coagulants (DOACs) are as safe and effective as conventional anticoagulants for treating venous thromboembolism (VTE), we have insufficient evidence justifying their use in patients with active cancer. We investigated the safety and effectiveness of DOACs in patients with active cancer. PATIENTS AND METHODS: To investigate the safety and efficacy of DOACs, we retrospectively extracted 312 consecutive patients with active cancer who were prescribed edoxaban, rivaroxaban or apixaban for VTE. RESULTS: The most common primary cancer sites were the lung, stomach, colon/rectum, hematology, ovary, and pancreas. Fifty patients (16%) discontinued DOACs due to clinically relevant bleeding; major bleeding events occurred in 18 patients (5.4%). Thrombosis reduced or resolved in 144 of 167 evaluable patients (86%). In particular, pulmonary embolism was reduced or resolved in 46 of 50 patients (92%). CONCLUSION: Our findings revealed that DOACs for cancer-associated VTE are as safe and effective as conventional anticoagulation therapy. PMID:34410964 | DOI:10.21873/invivo.12559 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer

xlomafota13 shared this article with you from Inoreader An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer Via In vivo (Athens, Greece) In Vivo. 2021 Sep-Oct;35(5):2809-2814. doi: 10.21873/invivo.12567. ABSTRACT BACKGROUND/AIM: The monoclonal antibody bevacizumab is a standard drug used in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) based chemotherapy in the first or second-line treatment of metastatic colorectal cancer (mCRC). Our previous study identified and subsequently validated 4 microRNAs in a small group of patients as predictors of the therapeutic response to bevacizumab combined with chemotherapy. The aim of this follow-up study is to confirm the predictive ability of these tissue miRNAs in a larger independent cohort of mCRC patients. PATIENTS AND METHODS: The retrospective study included 92 patients with generalized-radically inoperable tumors treated with the combined therapy of bevacizumab/FOLFOX in a standard regimen. RESULTS: Expression levels of candidate miRNA biomarkers (miR-92b-3p, miR-3156-5p, miR-10a-5p and miR-125a-5 p) were determined in tumor tissue specimens and statistically evaluated. MiR-92b-3p and miR-125a-5p were confirmed to be associated with radiological response according to RECIST criteria (p=0.005 and 0.05, respectively) and to be up-regulated in responders to bevacizumab/FOLFOX therapy. Higher levels of miR-92b-3p were also significantly associated with extended progression-free survival (p=0.024). CONCLUSION: We have successfully confirmed miR-92b-3p to be up-regulated in tumor tissue of mCRC patients with good response to bevacizumab/FOLFOX therapy. PMID:34410972 | DOI:10.21873/invivo.12567 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Severe Skin Disorders Due to Sorafenib Use After Nivolumab Treatment in Renal Cell Carcinoma Patients

xlomafota13 shared this article with you from Inoreader Severe Skin Disorders Due to Sorafenib Use After Nivolumab Treatment in Renal Cell Carcinoma Patients Via In vivo (Athens, Greece) In Vivo. 2021 Sep-Oct;35(5):2969-2974. doi: 10.21873/invivo.12591. ABSTRACT BACKGROUND: We report two cases in which severe skin disorders developed during sorafenib treatment in patients with renal cell carcinoma (RCC) who had previously received nivolumab. CASE REPORT: Case 1: A 50-year-old man with RCC received nivolumab as the fifth-line therapy followed by sorafenib as the sixth-line therapy. On day 15 of sorafenib administration, the patient was hospitalized with systemic erythema multiforme, acne-like skin rash, and hand-foot syndrome. Case 2: A 40-year-old man with RCC received nivolumab as the second-line therapy followed by sorafenib as the fifth-line treatment. On day 12 of sorafenib administration, the patient was hospitalized with an acne-like skin rash and hand-foot syndrome. The skin disorders in the two cases improved within 2-3 weeks after sorafenib discontinuation and the start of treatment with topical and oral steroids. CONCLUSION: When using sorafenib in patients previously treated with nivolumab, close attention should be paid to the onset of serious skin disorders. PMID:34410996 | DOI:10.21873/invivo.12591 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Liver Metastatic Colorectal Tumor Cells Change Their Phenotype During Consecutive Passages on Chick Embryo Chorioallantoic Membrane: Lessons from the Lab to the Clinic

xlomafota13 shared this article with you from Inoreader Liver Metastatic Colorectal Tumor Cells Change Their Phenotype During Consecutive Passages on Chick Embryo Chorioallantoic Membrane: Lessons from the Lab to the Clinic Via In vivo (Athens, Greece) In Vivo. 2021 Sep-Oct;35(5):2711-2718. doi: 10.21873/invivo.12555. ABSTRACT BACKGROUND/AIM: Colon cancer liver metastases with desmoplastic growth pattern (dGP) have a highly heterogeneous therapy response. The aim of the study was to evaluate the dGP liver metastasis molecular profile from a chemo-naive patient by mimicking metastatic process on an experimental chick embryo chorioallantoic membrane (CAM) model. MATERIALS AND METHODS: Three successive CAM passages of dGP human colorectal liver metastases were immunophenotyped for keratin (K) 8, and 20, CLIC1, VEGF, EGFR, CD34, podoplanin, Ki67, E-cadherin and vimentin. RESULTS: Metastatic cells gradually lost K20 while K8, E-cadherin and vimentin heterogeneously increased during passages. VEGF, CLIC 1, EGFR expression increased in metastatic cells especially at the tumor graft periphery. Scattered proliferating and non-proliferating podoplanin-positive tumor cells, lymphati c and blood vessels were heterogeneously detected in tumor xenografts depending on passage stage. CONCLUSION: By mimicking repetitive metastatic processes we proved that metastatic cells change their phenotype. This may explain why not all metastases have a similar response to therapy. PMID:34410960 | DOI:10.21873/invivo.12555 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Superior Mesenteric Vein Resection Followed by Porto-Jejunal Anastomosis During Pancreatoduodenectomy for Borderline Resectable Pancreatic Cancer - A Case Report and Literature Review

xlomafota13 shared this article with you from Inoreader Superior Mesenteric Vein Resection Followed by Porto-Jejunal Anastomosis During Pancreatoduodenectomy for Borderline Resectable Pancreatic Cancer - A Case Report and Literature Review Via In vivo (Athens, Greece) In Vivo. 2021 Sep-Oct;35(5):2975-2979. doi: 10.21873/invivo.12592. ABSTRACT BACKGROUND/AIM: Pancreatic cancer represents the most lethal abdominal malignancy, the only chance for achieving an improvement in terms of survival being represented by radical surgery. Although it has been considered that venous invasion represents a contraindication for resection, recently it has been demonstrated that in regards to overall survival after radical resection, it is similar to the one reported after standard pancreatoduodenectomy. CASE REPORT: A 53-year-old patient with no significant medical past was diagnosed with a borderline resectable pancreatic adenocarcinoma invading the superior mesenteric vein. The patient was submitted to pancreatoduodenectomy en bloc with superior mesenteric vein resection; the two jejunal veins were further anastomosed to the remnant portal vein. The postoperative outcome was favorable; the patient was dischar ged in the 10th postoperative day. CONCLUSION: Although technically more demanding, pancreatoduodenectomy en bloc with superior mesenteric vein resection and jejunal portal anastomosis is feasible and might offer a chance for long-term survival in borderline pancreatic head carcinoma invading the superior mesenteric vein. PMID:34410997 | DOI:10.21873/invivo.12592 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

SERPINB11 Expression Is Associated With Prognosis of High-grade Serous and Clear Cell Carcinoma of the Ovary

xlomafota13 shared this article with you from Inoreader <em>SERPINB11</em> Expression Is Associated With Prognosis of High-grade Serous and Clear Cell Carcinoma of the Ovary Via In vivo (Athens, Greece) In Vivo. 2021 Sep-Oct;35(5):2647-2653. doi: 10.21873/invivo.12547. ABSTRACT BACKGROUND/AIM: To evaluate the role of serine protease inhibitor B11 (SERPINB11) expression as a prognostic biomarker in high-grade serous carcinoma (HGSC) and clear cell carcinoma of the ovary (CCC). MATERIALS AND METHODS: We obtained tumor tissues from patients with HGSC (n=145) and CCC (n=59). We evaluated immunohistochemically the expression of SERPINB11 and investigated whether SERPINB11 expression affects platinum-resistance and the prognosis of HGSC and CCC. RESULTS: High expression of SERPINB11 was more common in CCC than in HGSC (57.6% vs. 28.3%; p<0.01), and SEPRINB11 expression did not correlate with platinum-resistance of HGSC and CCC. High expression of SERPINB11 was associated with worse progression-free survival and overall survival with marginal significance in HGSC; no relation between SERPINB11 expression and the prognosis of C CC was found. CONCLUSION: SERPINB11 expression maybe a prognostic biomarker for HGSC. PMID:34410952 | DOI:10.21873/invivo.12547 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Well-differentiated Spindle Cell Liposarcoma of the Larynx: A Rare Case Report and Review of Literature

xlomafota13 shared this article with you from Inoreader Well-differentiated Spindle Cell Liposarcoma of the Larynx: A Rare Case Report and Review of Literature Via In vivo (Athens, Greece) In Vivo. 2021 Sep-Oct;35(5):2779-2783. doi: 10.21873/invivo.12563. ABSTRACT BACKGROUND: Liposarcoma of the larynx is a rare entity. Well-differentiated spindle cell liposarcoma of the larynx has not been yet reported in the literature. CASE REPORT: We report the first case of well-differentiated spindle cell liposarcoma of the larynx on a 59-year-old male who presented with change of voice and phlegmy cough for several months. Laryngoscopy revealed a mucosal covered pedunculated mass on the supraglottis. Computerized tomography (CT) scan showed a low-attenuation mass causing moderate narrowing of the airway. The lesion was excised. Grossly, a 4.2 cm ovoid, solid and soft mass with homogeneously white-gray and rubbery cut surface was identified. Microscopic examination revealed a well-demarcated neoplasm composed of predominantly atypical and pleomorphic spindle cells distributed in collagenous stroma, with admixed adipocytes show ing variation in cell size and rare lipoblasts. Immunohistochemical stains showed that the spindle cells were positive for MDM2, CDK4, and CD34. Overall, the histology and immunoprofile are consistent with a well-differentiated liposarcoma, spindle cell type. Due to the positive resection margin, the patient subsequently received endoscopic local re-excision with a carbon dioxide laser. He did well at 4 months after primary excision. CONCLUSION: This case illustrates that while well-differentiated spindle cell liposarcoma rarely occurs in the larynx, it should be considered in the differential diagnosis of patients with laryngeal lesions. A panel of immunohistochemistry markers including MDM2, CDK4 and CD34 is helpful to render accurate diagnosis. Wide excision with long-term follow-up is necessary for this rare variant of liposarcoma. PMID:34410968 | DOI:10.21873/invivo.12563 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Sinonasal carcinoma and Ohngren's line: Retrospective cohort study of 39 patients

xlomafota13 shared this article with you from Inoreader Sinonasal carcinoma and Ohngren's line: Retrospective cohort study of 39 patients Via Latest Issue of Clinical Otolaryngology RSS Feed View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Middle ear adenomatous neuroendocrine tumours: Single institution experience with five cases

xlomafota13 shared this article with you from Inoreader Middle ear adenomatous neuroendocrine tumours: Single institution experience with five cases Via Latest Issue of Clinical Otolaryngology RSS Feed View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Efficacy and safety of intraglandular botulinum toxin injections for treatment of sialadenosis

xlomafota13 shared this article with you from Inoreader Efficacy and safety of intraglandular botulinum toxin injections for treatment of sialadenosis Via Latest Issue of Clinical Otolaryngology RSS Feed View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Anterior ethmoid artery septal flap for endoscopic reconstruction of frontal sinus cerebrospinal fluid leak

xlomafota13 shared this article with you from Inoreader Anterior ethmoid artery septal flap for endoscopic reconstruction of frontal sinus cerebrospinal fluid leak Via Latest Issue of Clinical Otolaryngology RSS Feed View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.